D-Index & Metrics Best Publications

Piotr Kuna

Medical University of Lodz
Poland

Immunology

Poland

2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Immunology D-index 71 Citations 32,248 445 World Ranking 1444 National Ranking 2

Research.com Recognitions

Awards & Achievements

2023 - Research.com Immunology in Poland Leader Award

2022 - Research.com Immunology in Poland Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

Internal medicine
Asthma
Disease

His scientific interests lie mostly in Asthma, Immunology, Internal medicine, Allergy and Placebo. He combines subjects such as Quality of life, Allergen immunotherapy, Allergen, Family medicine and Intensive care medicine with his study of Asthma. In his work, Basophil and Immunoglobulin E is strongly intertwined with Histamine, which is a subfield of Immunology.

His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Endocrinology and Placebo-controlled study. His Allergy research is multidisciplinary, incorporating elements of Visual analogue scale, Quality of life, rhinorrhea and Position paper. His Placebo research incorporates themes from Benralizumab, Anesthesia, Exacerbation, Adverse effect and Reslizumab.

His most cited work include:

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) (3245 citations)
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision (480 citations)
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs (384 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Asthma, Immunology, Internal medicine, Allergy and Placebo. His Asthma study incorporates themes from Anesthesia, Pediatrics, Family medicine and Intensive care medicine. As part of the same scientific family, Piotr Kuna usually focuses on Family medicine, concentrating on Health care and intersecting with Quality of life.

He has included themes like Peripheral blood mononuclear cell and Histamine in his Immunology study. His Internal medicine research incorporates elements of Gastroenterology and Endocrinology. Allergy is closely attributed to Dermatology in his work.

He most often published in these fields:

Asthma (42.61%)
Immunology (29.56%)
Internal medicine (28.98%)

What were the highlights of his more recent work (between 2018-2021)?

Asthma (42.61%)
Internal medicine (28.98%)
Allergy (15.93%)

In recent papers he was focusing on the following fields of study:

Piotr Kuna mostly deals with Asthma, Internal medicine, Allergy, Family medicine and Intensive care medicine. His work carried out in the field of Asthma brings together such families of science as mHealth, Integrated care, Health care, Observational study and Disease. His work in the fields of Internal medicine, such as Aspirin, Clinical significance and Adverse effect, overlaps with other areas such as In patient.

Allergy and COPD are commonly linked in his work. He interconnects Psychological intervention, Guideline, MEDLINE and Quality of life in the investigation of issues within Family medicine. His Intensive care medicine research is multidisciplinary, relying on both Benralizumab, Mepolizumab, Multimorbidity, Allergen and Pharmacotherapy.

Between 2018 and 2021, his most popular works were:

Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. (63 citations)
2019 ARIA Care pathways for allergen immunotherapy (54 citations)
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (49 citations)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

J. Bousquet;H. J. Schünemann;B. Samolinski;P. Demoly.
The Journal of Allergy and Clinical Immunology (2012)

7758 Citations

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

J. Bousquet;N. Khaltaev;A. A. Cruz;J. Denburg.
Allergy (2008)

6493 Citations

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision

Jan L. Brożek;Jean Bousquet;Ioana Agache;Arnav Agarwal.
The Journal of Allergy and Clinical Immunology (2017)

2189 Citations

International consensus on (ICON) pediatric asthma

N. G. Papadopoulos;H. Arakawa;A. Custovic;J. Gern.
Allergy (2012)

751 Citations

Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009

G Walter Canonica;Jean Bousquet;Thomas Casale;Richard F Lockey.
World Allergy Organization Journal (2009)

712 Citations

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Parameswaran Nair;Sally Wenzel;Klaus F. Rabe;Arnaud Bourdin.
The New England Journal of Medicine (2017)

689 Citations

Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.

Canonica Gw;Bousquet J;Casale T;Lockey Rf.
Allergy (2009)

675 Citations

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

Allen P Kaplan;Dennis Ledford;Mark Ashby;Janice Canvin.
The Journal of Allergy and Clinical Immunology (2013)

568 Citations

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

Mario Castro;Sally E Wenzel;Eugene R Bleecker;Emilio Pizzichini.
The Lancet Respiratory Medicine (2014)

508 Citations

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.

Sven-Erik Dahlén;Kerstin Malmström;Ewa Nizankowska;Barbro Dahlén.
American Journal of Respiratory and Critical Care Medicine (2002)

419 Citations

If you think any of the details on this page are incorrect, let us know.